Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Solid Tumors × Palonosetron × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Vomiting 24 Nausea 18 Neoplasms 8 Breast Neoplasms 6 Lymphoma 3 Stomach Neoplasms 2 Rectal Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Breast Neoplasms, Male 2 Weight Loss 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Sarcoma 1 Pancreatic Neoplasms 1 Neoplasms, Germ Cell and Embryonal 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Liver Neoplasms 1 Leukemia 1 Inflammatory Breast Neoplasms 1 Hematologic Neoplasms 1 Glioma 1 Genital Neoplasms, Female 1 Gastrointestinal Neoplasms 1 Gallbladder Neoplasms 1 Carcinoma, Hepatocellular 1 Brain Neoplasms 1

Interventions

Sunitinib 4 Cyclophosphamide 4 Capecitabine 4 Bevacizumab 4 pazopanib 3 Topotecan 3 Paclitaxel 3 Docetaxel 3 Carboplatin 3 temsirolimus 2 liposomal doxorubicin 2 fludarabine 2 Sorafenib 2 Panobinostat 2 NVP-BKM120 2 Lapatinib 2 Irinotecan 2 Immune Checkpoint Inhibitors 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Bortezomib 2 vadimezan 1 spartalizumab 1 somatostatin receptor 2 1 selinexor 1 selicrelumab 1 perifosine 1 pegylated granulocyte colony-stimulating factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02135510 2020-03-31

MEDEA

Amsterdam UMC, location VUmc

Phase 3 Completed

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡